Journal article
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation
Blood, Vol.108(8), pp.2712-2719
10/15/2006
DOI: 10.1182/blood-2006-03-014001
PMCID: PMC1895576
PMID: 16809616
Abstract
B cells currently are not viewed as being capable of producing granzyme B or being cytotoxic. We found that B-chronic lymphocytic leukemia (B-CLL) cells treated with interleukin-21 (IL-21) produce low levels of granzyme B. The addition of either CpG oligodeoxynucleotide (ODN) or anti-B-cell-receptor antibody (anti-BCR) to IL-21 results in enhanced production of functional granzyme B by B-CLL cells. B-CLL cells treated with IL-21 and CpG ODN undergo apoptosis and are able to induce apoptosis of untreated bystander B-CLL cells. This effect can be inhibited by anti-granzyme B antibody. Benign human B cells, Epstein-Barr virus (EBV)-transformed lymphoblasts, and many standard lymphoma cell lines produce high levels of granzyme B in response to IL-21 and anti-BCR. Our results suggest that the ability to induce production of functional granzyme B by B cells could open new approaches to the therapy of B-CLL and other B-cell malignancies. Our findings also have significant implications for our understanding of the role of B cells for immune regulation and for a variety of immune phenomena, including cancer immunity, autoimmunity, and infectious immunity.
Details
- Title: Subtitle
- B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation
- Creators
- Bernd Jahrsdörfer - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CitySue E Blackwell - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CityJames E Wooldridge - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CityJian Huang - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CityMelinda W Andreski - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CityLaura S Jacobus - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CityChristiana M Taylor - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa CityGeorge J Weiner - From the Department of Internal Medicine, The Holden Comprehensive Cancer Center; and Department of Statistics, University of Iowa, Iowa City
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.108(8), pp.2712-2719
- Publisher
- 2006 by The American Society of Hematology
- DOI
- 10.1182/blood-2006-03-014001
- PMID
- 16809616
- PMCID
- PMC1895576
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 10/15/2006
- Academic Unit
- Statistics and Actuarial Science; Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Holden Comprehensive Cancer Center; Internal Medicine
- Record Identifier
- 9984094504502771
Metrics
38 Record Views